Online inquiry

IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2049MR)

This product GTTS-WQ2049MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2049MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14992MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ15102MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ15235MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ9567MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ3373MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ4069MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ10874MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ15530MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-7858
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW